IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i3d10.1007_s40273-020-00996-2.html
   My bibliography  Save this article

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

Author

Listed:
  • Ronan Mahon

    (Novartis Ireland Limited)

  • Andrea Lang

    (Novartis Sverige AB)

  • Pamela Vo

    (Novartis Pharma AG)

  • Jasper Huels

    (Novartis Pharma AG)

  • Philip Cooney

    (Novartis Ireland Limited)

  • Andriy Danyliv

    (Novartis Ireland Limited)

  • Umakanth Vudumula

    (Novartis Healthcare Private Limited)

  • Sreelatha Vadapalle

    (Novartis Healthcare Private Limited)

  • Farooq Maniyar

    (Basildon and Thurrock University Hospitals and Queen Mary University)

  • Peter J. Goadsby

    (King’s College London)

Abstract

Background Migraine is a common neurological disease that disproportionately affects females and has a peak incidence during productive years, resulting in significant burden. Objective The aim of the study was to determine the cost effectiveness of erenumab for the preventive treatment of migraine. Methods A hybrid decision-tree plus Markov model was developed to evaluate the cost effectiveness of erenumab as a migraine treatment compared with best supportive care only for patients experiencing at least 4 monthly migraine days for whom at least two prior preventive treatments had failed. Clinical efficacy data were based on results from four randomized controlled trials of erenumab against placebo. The primary outcomes were costs, migraine days, and quality-adjusted life-years (QALYs). An incremental cost-effectiveness ratio (ICER) was estimated as the cost per QALY gained. The cost per migraine day avoided was also estimated, as were disaggregated direct and indirect costs. The analysis was conducted from Swedish societal and healthcare system perspectives based on total migraine, chronic migraine and episodic migraine populations, using a discount rate of 3% applied to both costs and health benefits and using year 2019 values. Results In the base-case deterministic analyses, erenumab treatment resulted in ICERs of Swedish krona (SEK) 34,696 (€3310) and SEK301,565 (€28,769) per QALY gained in the total migraine and episodic migraine populations, respectively. Erenumab was dominant in the chronic migraine population. In the total migraine population, the use of erenumab resulted in a net benefit to society of SEK81,739 (€7773) per patient, assuming a willingness-to-pay threshold of SEK300,000 (€28,528) per QALY. Conclusions Our analysis suggests that erenumab is a cost-effective treatment for migraine with a willingness-to-pay threshold of SEK300,000 per QALY.

Suggested Citation

  • Ronan Mahon & Andrea Lang & Pamela Vo & Jasper Huels & Philip Cooney & Andriy Danyliv & Umakanth Vudumula & Sreelatha Vadapalle & Farooq Maniyar & Peter J. Goadsby, 2021. "Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden," PharmacoEconomics, Springer, vol. 39(3), pages 357-372, March.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00996-2
    DOI: 10.1007/s40273-020-00996-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-020-00996-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-020-00996-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Journal round-up: PharmacoEconomics 39(3)
      by Chris Sampson in The Academic Health Economists' Blog on 2021-04-05 06:00:12

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00996-2. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.